---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-22-003180"
form_type: "8-K"
ticker: "LTRN"
cik: "0001763950"
company_name: "Lantern Pharma Inc."
filed_at: "2022-01-24T23:59:59+00:00"
generated_at: "2026-06-27T16:17:05.611523+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Lantern Pharma receives Rare Pediatric Disease and Orphan Drug designations for LP-184 in ATRT

## Summary
- FDA grants Rare Pediatric Disease Designation and Orphan Drug Designation for LP-184 to treat atypical teratoid rhabdoid tumor (ATRT).
- LP-184 is the third Lantern program to receive Orphan Drug Designation; prior designations for pancreatic cancer and malignant glioma.
- Rare Pediatric Disease Designation may qualify Lantern for a Priority Review Voucher upon FDA approval of LP-184.
- ATRT is an aggressive CNS tumor; nearly 90% of pediatric cases involve SMARCB1 mutations, which LP-184 targets.

## SEC filing metadata
- accession: 0001213900-22-003180
- form_type: 8-K
- ticker: LTRN
- cik: 0001763950
- company_name: Lantern Pharma Inc.
- filed_at: 2022-01-24T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1763950/000121390022003180/0001213900-22-003180-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1763950/000121390022003180/ea154399-8k_lantern.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-22-003180
- JSON: https://secwatch.observer/filing/0001213900-22-003180.json
- Plain text: https://secwatch.observer/filing/0001213900-22-003180.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.